author-photo

Richard Pazdur

Food and Drug Administration
Center for Drug Evaluation and Research
University of Texas MD Anderson Cancer Center

415

Papers

15436

Citations

Citation Trend

Filter By

Papers (282) Sort By

Journal Conference Others

Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop.

2021 Nature Reviews Urology
Show All
- Source
- Cite
- Save
Citations (0)
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
An FDA-pooled analysis of frontline combination treatment benefits by risk groups in metastatic renal cell carcinoma (mRCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
An FDA pooled analysis: Characteristics and outcomes of patients with nonmetastatic castration-resistant prostate cancer, based on prior history of prostatectomy and/or radiation therapy.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Immunotherapy for Patients With Small-Cell Lung Cancer-2 Gains, 2 Losses.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Contribution of Early Clinical Benefit End Points to Decreased Lung Cancer Mortality Rates.

2021 JAMA Oncology
- Harpreet Singh
- Richard Pazdur
Show All
- Source
- Cite
- Save
Citations (2)
The Drug-Dosing Conundrum in Oncology - When Less Is More.

2021 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (0)
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.

2021 Oncologist
Show All
- Source
- Cite
- Save
Citations (0)